{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Sarepta Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"SRPT"},"Address":{"label":"Address","value":"215 FIRST STREET,SUITE 415, CAMBRIDGE, Massachusetts, 02142, United States"},"Phone":{"label":"Phone","value":"+1 617 274-4000"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development."},"CompanyUrl":{"label":"Company Url","value":"https://www.sarepta.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bilal Arif","title":"Chief Technical Operations Officer & Executive VP"},{"name":"Douglas S. Ingram","title":"President, Chief Executive Officer & Director"},{"name":"Louise Rodino-Klapac","title":"Chief Scientific Officer & Executive VP"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}